139 related articles for article (PubMed ID: 30914526)
1. [Ⅲ.Surgery for Platinum Sensitive Recurrent Epithelial Ovarian Cancer].
Nagao S
Gan To Kagaku Ryoho; 2019 Feb; 46(2):240-243. PubMed ID: 30914526
[No Abstract] [Full Text] [Related]
2. [Ⅰ. Secondary Cytoreductive Surgery for Platinum-Sensitive Recurrent Ovarian Cancer -Review and Consideration from Recent International Phase Ⅲ Trials].
Yabuno A; Hasegawa K
Gan To Kagaku Ryoho; 2021 Feb; 48(2):191-194. PubMed ID: 33597357
[No Abstract] [Full Text] [Related]
3. Epithelial Ovarian Cancer and Cancer Stem Cells.
Soliman AA; Elzarkaa AA; Malik E
Adv Exp Med Biol; 2021; 1330():21-32. PubMed ID: 34339028
[TBL] [Abstract][Full Text] [Related]
4. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.
Chuang YT; Chang CL
Taiwan J Obstet Gynecol; 2012 Sep; 51(3):336-41. PubMed ID: 23040913
[TBL] [Abstract][Full Text] [Related]
5. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
6. Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Boran N; Hizli D; Yilmaz S; Turan T; Celik B; Karabuk E; Isikdogan Z; Tulunay G; Kose MF
J Surg Oncol; 2012 Sep; 106(4):369-75. PubMed ID: 22441998
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
8. Optimizing treatment in recurrent epithelial ovarian cancer.
Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
[TBL] [Abstract][Full Text] [Related]
9. Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
Hirasawa T; Machida H; Iida T; Ikeda M; Shida M; Mikami M
Tokai J Exp Clin Med; 2018 Sep; 43(3):85-89. PubMed ID: 30191541
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.
Wang PH
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):623-624. PubMed ID: 30342639
[No Abstract] [Full Text] [Related]
11. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
12. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
13. The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
van de Laar R; Zusterzeel PL; Van Gorp T; Ottevanger PB; Massuger LF; Kruitwagen RF
Gynecol Oncol; 2013 Dec; 131(3):561-6. PubMed ID: 24060415
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
[No Abstract] [Full Text] [Related]
15. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
16. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Cadron I; Abdulkadir L; Despierre E; Berteloot P; Neven P; Leunen K; Amant F; Vergote I
Gynecol Oncol; 2013 Jan; 128(1):34-37. PubMed ID: 23063762
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
Harrison R; Zighelboim I; Cloven NG; Marcus JZ; Coleman RL; Karam A
Gynecol Oncol; 2021 Dec; 163(3):448-452. PubMed ID: 34686355
[No Abstract] [Full Text] [Related]
19. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
20. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
Tomao F; D'Incalci M; Biagioli E; Peccatori FA; Colombo N
Cancer; 2017 Sep; 123(18):3450-3459. PubMed ID: 28678350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
